CL2022003304A1 - Anticuerpos anti-pd-1 - Google Patents
Anticuerpos anti-pd-1Info
- Publication number
- CL2022003304A1 CL2022003304A1 CL2022003304A CL2022003304A CL2022003304A1 CL 2022003304 A1 CL2022003304 A1 CL 2022003304A1 CL 2022003304 A CL2022003304 A CL 2022003304A CL 2022003304 A CL2022003304 A CL 2022003304A CL 2022003304 A1 CL2022003304 A1 CL 2022003304A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- antigen
- therapeutic
- compositions
- cell death
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a nuevos anticuerpos anti-PD-1 (muerte celular programada 1) y fragmentos de unión al antígeno de los mismos para métodos terapéuticos y de diagnóstico y composiciones que los utilizan.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063029962P | 2020-05-26 | 2020-05-26 | |
US202063039686P | 2020-06-16 | 2020-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022003304A1 true CL2022003304A1 (es) | 2023-04-14 |
Family
ID=76808128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003304A CL2022003304A1 (es) | 2020-05-26 | 2022-11-24 | Anticuerpos anti-pd-1 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20210380696A1 (es) |
EP (1) | EP4157876A1 (es) |
JP (1) | JP2023528778A (es) |
KR (1) | KR20230015997A (es) |
CN (1) | CN115956087A (es) |
AU (1) | AU2021280232A1 (es) |
BR (1) | BR112022023989A2 (es) |
CA (1) | CA3181776A1 (es) |
CL (1) | CL2022003304A1 (es) |
CO (1) | CO2022018416A2 (es) |
CR (1) | CR20220596A (es) |
DO (1) | DOP2022000264A (es) |
EC (1) | ECSP22092185A (es) |
IL (1) | IL298431A (es) |
MX (1) | MX2022014974A (es) |
PE (1) | PE20231076A1 (es) |
TW (1) | TW202216765A (es) |
WO (1) | WO2021242663A1 (es) |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
NZ548612A (en) | 2004-02-09 | 2009-11-27 | Human Genome Sciences Inc | Albumin fusion proteins comprising tandem GLP-1 |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
CA2823044C (en) | 2010-12-31 | 2022-08-16 | Jay M. Short | Express humanization of antibodies |
AU2016332725A1 (en) | 2015-09-29 | 2018-03-22 | Celgene Corporation | PD-1 binding proteins and methods of use thereof |
WO2017189964A2 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CA3065516A1 (en) | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
AU2020286444A1 (en) | 2019-06-05 | 2021-12-23 | Anaptysbio, Inc. | PD-1 agonist and method of using same |
-
2021
- 2021-05-24 KR KR1020227045536A patent/KR20230015997A/ko not_active Application Discontinuation
- 2021-05-24 EP EP21739197.8A patent/EP4157876A1/en active Pending
- 2021-05-24 PE PE2022002742A patent/PE20231076A1/es unknown
- 2021-05-24 JP JP2022572362A patent/JP2023528778A/ja active Pending
- 2021-05-24 AU AU2021280232A patent/AU2021280232A1/en active Pending
- 2021-05-24 IL IL298431A patent/IL298431A/en unknown
- 2021-05-24 CN CN202180037658.8A patent/CN115956087A/zh active Pending
- 2021-05-24 WO PCT/US2021/033823 patent/WO2021242663A1/en active Application Filing
- 2021-05-24 TW TW110118624A patent/TW202216765A/zh unknown
- 2021-05-24 US US17/328,050 patent/US20210380696A1/en active Pending
- 2021-05-24 CA CA3181776A patent/CA3181776A1/en active Pending
- 2021-05-24 CR CR20220596A patent/CR20220596A/es unknown
- 2021-05-24 MX MX2022014974A patent/MX2022014974A/es unknown
- 2021-05-24 BR BR112022023989A patent/BR112022023989A2/pt unknown
-
2022
- 2022-11-23 DO DO2022000264A patent/DOP2022000264A/es unknown
- 2022-11-24 CL CL2022003304A patent/CL2022003304A1/es unknown
- 2022-12-09 EC ECSENADI202292185A patent/ECSP22092185A/es unknown
- 2022-12-19 CO CONC2022/0018416A patent/CO2022018416A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20231076A1 (es) | 2023-07-17 |
BR112022023989A2 (pt) | 2023-02-07 |
CO2022018416A2 (es) | 2022-12-30 |
ECSP22092185A (es) | 2023-01-31 |
AU2021280232A1 (en) | 2022-12-15 |
DOP2022000264A (es) | 2023-01-31 |
JP2023528778A (ja) | 2023-07-06 |
IL298431A (en) | 2023-01-01 |
MX2022014974A (es) | 2023-01-11 |
CA3181776A1 (en) | 2021-12-02 |
US20210380696A1 (en) | 2021-12-09 |
EP4157876A1 (en) | 2023-04-05 |
KR20230015997A (ko) | 2023-01-31 |
TW202216765A (zh) | 2022-05-01 |
WO2021242663A1 (en) | 2021-12-02 |
CN115956087A (zh) | 2023-04-11 |
CR20220596A (es) | 2023-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CL2020001048A1 (es) | Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) | |
PE20190510A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
ECSP099656A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
BR112014010532A2 (pt) | anticorpo e métodos para inibição seletiva de respostas de célula-t | |
BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
CL2021003327A1 (es) | Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089). | |
AR121599A1 (es) | Anticuerpos | |
CO2023017156A2 (es) | Anticuerpos anti-sirp-alfa | |
CL2022003515A1 (es) | Moléculas agonistas de unión al antígeno cd28 que se dirigen a her2 | |
CL2022001554A1 (es) | Anticuerpos anti-mertk y métodos de uso de los mismos | |
ECSP21052193A (es) | Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r | |
MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
CO2022000832A2 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
DOP2022000295A (es) | Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413 | |
CO2022018807A2 (es) | Captadores de células inmunitarias biespecíficas con especificidad de unión para hla-g y otro antígeno | |
CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
CL2021002603A1 (es) | Anti–cd25 para el agotamiento de células específicas de tumores (divisional de la solicitud no. 202002340) | |
CO2022018416A2 (es) | Anticuerpos anti-pd-1 | |
CL2023000084A1 (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas | |
ECSP22004680A (es) | Anticuerpos anti-angpt2 | |
CO2023015859A2 (es) | Anticuerpos para tratar alfa-sinucleinopatías |